The present invention discloses a synthetic polypeptide comprising “n” number of repeats of a sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2. The synthetic polypeptide as disclosed herein is represented by an amino acid sequence selected 5 from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO:...

The present disclosure discloses a bioengineered formulation comprising: (a) a modified collagen peptide having a molecular weight in the range of 20-80 kDa, and with a degree of substitution in the range of 20-75%; and (b) a modified hyaluronic acid having a molecular weight in the range of 10-100 kDa, and with a d...

The present disclosure provides a process for obtaining an expanded primed mesenchymal stem cell population. In the process, the MSCs are cultured in the culture medium comprising a corneal stromal stem cell derived-conditioned medium to obtain the expanded population of the primed mesenchymal stem cell population a...

The present disclosure discloses a xeno-free bio-ink formulation amenable to be printed using a 3D printer. The bio-ink formulation exhibits optimum viscosity in the range of 1690-5300 cP. The present disclosure discloses a bio-printed corneal lenticule obtained from the bio-ink formulation. The bio-printed corneal ...

The present disclosure discloses methods for culturing stem cells in three-dimensional methods. Said method is either a spheroid-based method or a microcarrier-based method. The process as described herein leads to the expansion of the stem cells to obtain an expanded population of the stem cells, and a stem cell de...

The present disclosure discloses a Liquid Cornea composition comprising: at least one polymer; an antifibrinolytic agent; decellularized extracellular matrix; at least one extracellular matrix cross-linker; and calcium chloride (CaCl2). Also provided is a method for preparing the liquid cornea composition. The pr...

The present disclosure discloses a Liquid Cornea composition comprising: at least one polymer; an antifibrinolytic agent; decellularized extracellular matrix; human corneal cell suspension; at least one extracellular matrix cross-linker; and calcium chloride (CaCl2). Also provided is a method for preparing the li...

Provided in the present disclosure are biopolymer formulations comprising thiolated gelatin and methacrylated hyaluronic acid. Said formulations are useful for corneal applications, by way of example for treatment of disease of or damage to a cornea in a subject. Also provided are methods for preparing the biopolyme...

There is provided herein methods generating a population of primed mesenchymal stem cell-derived exosomes. A method in accordance with the disclosure may comprise expanding a population of mesenchymal stem cells (MSCs) in culture; administering one or more priming agents in the culture to prime the population of MSC...

ABSTRACT LIVER SPHEROID DISEASE MODELS Disclosed is a method of inducing non-alcoholic steato-hepatitis in a multi-component liver spheroid. The method includes harvesting or reviving a cryopreserved sample of two or more distinct primary liver cell types and seeding a mixture of at least two or ...

AS ATTACHED

Disclosed is a method of inducing non-alcoholic steato-hepatitis in a multi-component liver spheroid. The method includes harvesting or reviving a cryopreserved sample of two or more distinct primary liver cell types and seeding a mixture of at least two or more distinct primary liver cell types to generate a multi-...

ABSTRACT A LENTICULE, METHOD OF PREPARATION AND IMPLEMENTATIONS THEREOF The present disclosure provides a three-dimensional hydrogel prepared using a bioink composition comprising methacrylated hyaluronic acid, 5 methacrylated gelatin, a photoinitiator and a photoabsorber; and a method for preparing the threedi...